NCT07201831View on ClinicalTrials.gov

A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population

Not yet recruitingOBSERVATIONAL
Enrollment

1,320

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

December 23, 2025

Study Completion Date

December 23, 2025

Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
OTHER

No treatment given

No treatment given

Trial Locations (5)

08536

Novo Nordisk Investigational Site, Plainsboro

Unknown

Novo Nordisk Investigational Site, Mississauga

Novo Nordisk Investigational Site, Puteaux

Novo Nordisk Investigational Site, Mainz

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY